{"disease":{"id":"metastatic-soft-tissue-sarcoma","name":"Metastatic soft tissue sarcoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Soft Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03793166","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1175,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT04671693","title":"A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06422806","title":"Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06797999","title":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Adcendo ApS","has_results":false},{"nct_id":"NCT03138161","title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":false},{"nct_id":"NCT01574716","title":"Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":209,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT02357810","title":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00919269","title":"Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03793361","title":"Phase II Study of Regorafenib as Maintenance Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"Centre Oscar Lambret","has_results":false},{"nct_id":"NCT01514188","title":"Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":true},{"nct_id":"NCT04551430","title":"Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03317457","title":"Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03965234","title":"Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03590210","title":"Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"University Medicine Greifswald","has_results":false},{"nct_id":"NCT02609984","title":"Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04579757","title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Hutchmed","has_results":true},{"nct_id":"NCT05694871","title":"Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06498648","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04200443","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03022448","title":"Geriatric Assessmen of Elderly \"Unsuited\" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT02235701","title":"Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":true},{"nct_id":"NCT05836571","title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT00525057","title":"Dalteparin in Preventing DVT in Participants With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04028063","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT00112463","title":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06474676","title":"T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03495921","title":"A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Gradalis, Inc.","has_results":true},{"nct_id":"NCT04900766","title":"A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04725331","title":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Transgene","has_results":false},{"nct_id":"NCT04138381","title":"Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Grupo Espanol de Investigacion en Sarcomas","has_results":false},{"nct_id":"NCT03670069","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04458922","title":"Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00638898","title":"Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04854018","title":"Indo-cyanine Green (ICG) in Paediatric Oncology MIS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Birmingham Women's and Children's NHS Foundation Trust","has_results":false},{"nct_id":"NCT07283731","title":"Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03660930","title":"Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT06968988","title":"Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03009201","title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04616248","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT01014598","title":"Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT05100628","title":"A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Noxopharm Limited","has_results":true},{"nct_id":"NCT03397186","title":"Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}